Company intelligence / Profile preview

FinalSpark

Vevey, Vaud, Switzerlandfinalspark.com ↗

Ownership: Private
Employees: ~8
Development stage: Preclinical

Overview

FinalSpark has developed the world’s first commercial bioprocessors using living human brain tissue. Their Neuroplatform allows global researchers to remotely conduct experiments on neuronal tissues in vitro, supporting long-term electrophysiological studies. The technology promises energy efficiency far beyond traditional silicon chips and aims to enable the creation of “living processors.” Nine institutions currently have access, with dozens more expressing interest. No clinical results as this is not a therapeutic product.

Industry: Non-Drug Biotech

Partnerships

Collaborations with at least nine academic/research institutions globally for use of the Neuroplatform.

Beyond the preview

Go deeper on FinalSpark.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FinalSpark.

Explore the full profile